Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 12/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 12/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22855681 | 0.96 | PRMT5 (0.44) | PRMT5WDR77MAPTCYP11B1CYP11B2 | |
| SCHEMBL28502959 | 0.90 | PRMT5 (0.38) | PRMT5WDR77MAPTCRBNROCK2 | |
| SCHEMBL22855632 | 0.86 | ALDH1A1 (0.53) | MAPTPIM1PIM2JAK1CRBN | |
| SCHEMBL22855475 | 0.85 | ALDH1A1 (0.45) | MAPTROCK2 | |
| SCHEMBL22855214 | 0.85 | GFER (0.38) | PRMT5WDR77JAK1ROCK2CYP3A4 | |
| SCHEMBL23240775 | 0.82 | PRMT5 (0.53) | PRMT5WDR77MAPTKCNH2JAK1 | |
| SCHEMBL22855639 | 0.82 | ALDH1A1 (0.46) | MAPTROCK2 | |
| SCHEMBL23212394 | 0.80 | MAPT (0.46) | PRMT5WDR77MAPTCYP11B1CYP11B2 | |
| SCHEMBL22855213 | 0.79 | CDC7 (0.33) | PRMT5WDR77KCNH2PIM1PIM2 | |
| SCHEMBL29548144 | 0.78 | MAPT (0.44) | PRMT5WDR77MAPTCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473280-B2 | Substituted tricyclic compound as PRMT5 inhibitor and use thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| CN-114466846-B | Substituted tricyclic compounds as PRMT5 inhibitors and application thereof | 南京圣和药业股份有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20240116918-A1 | SUBSTITUTED TRICYCLIC COMPOUND AS PRMT5 INHIBITOR AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
| CN-112645946-B | Substituted tricyclic compounds as PRMT5 inhibitors and application thereof | 南京圣和药业股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-112125886-B | Tricyclic compounds as PRMT5 inhibitors and application thereof | 南京圣和药物研发有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4043459-A1 | SUBSTITUTED TRICYCLIC COMPOUND AS PRMT5 INHIBITOR AND USE THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021068953-A1 | SUBSTITUTED TRICYCLIC COMPOUND AS PRMT5 INHIBITOR AND USE THEREOF | 南京圣和药业股份有限公司 | 2021-04-15 | — | — | WO | disclosed |
| WO-2020259478-A1 | TRICYCLIC COMPOUND AS PRMT5 INHIBITOR AND APPLICATION THEREOF | 南京圣和药物研发有限公司 | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473280-B2 | Substituted tricyclic compound as PRMT5 inhibitor and use thereof | PRMT5, PRMT1, PRMT8 | PRMT5 1/4885WDR77 40/4885MAPT 1796/4885 |
| US-20240116918-A1 | SUBSTITUTED TRICYCLIC COMPOUND AS PRMT5 INHIBITOR AND USE THEREOF | PRMT5, PRMT1, PRMT8 | PRMT5 1/4885WDR77 40/4885MAPT 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.